Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675590 | 0.93 | RAB9A (0.64) | RAB9ANPC1L3MBTL1CTRB1SMN1; SMN2 | |
| SCHEMBL3167334 | 0.85 | RAB9A (0.57) | RAB9ANPC1L3MBTL1CTRB1SMN1; SMN2 | |
| SCHEMBL3182929 | 0.84 | NPC1 (0.56) | RAB9ANPC1L3MBTL1CTRB1SMN1; SMN2 | |
| SCHEMBL5737141 | 0.83 | NPC1 (0.55) | RAB9ANPC1L3MBTL1CTRB1SMN1; SMN2 | |
| SCHEMBL22638725 | 0.83 | NPC1 (0.63) | RAB9ANPC1L3MBTL1CTRB1SMN1; SMN2 | |
| SCHEMBL13506550 | 0.82 | NPC1 (0.54) | RAB9ANPC1L3MBTL1CTRB1SMN1; SMN2 | |
| SCHEMBL7469639 | 0.82 | NPC1 (1.00) | RAB9ANPC1L3MBTL1SMN1; SMN2GAA | |
| SCHEMBL30659283 | 0.82 | NPC1 (1.00) | RAB9ANPC1L3MBTL1SMN1; SMN2GAA | |
| SCHEMBL2876191 | 0.81 | NPC1 (0.53) | RAB9ANPC1L3MBTL1CTRB1SMN1; SMN2 | |
| SCHEMBL2539997 | 0.80 | NPC1 (0.67) | RAB9ANPC1L3MBTL1CTRB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1964925-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-1,2,3,4 -TETRAHYDROQUINOLINES | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-03-30 | — | — | EP | disclosed |
| EP-1941881-B1 | Naphthalene derivatives for the treatment of dermatitis and psoriasis | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-8796460-B2 | Compounds for inhibiting KSP kinesin activity | Mercky Sharp & Dohme Corp. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796460-B2 | Compounds for inhibiting KSP kinesin activity | Mercky Sharp & Dohme Corp. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8754221-B2 | Optically active cyclic alcohol compound and method for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20130237708-A1 | Optically Active Cyclic Alcohol Compound And Method For Preparing The Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-12 | — | — | US | disclosed |
| EP-2371820-B1 | Optically active cyclic alcohol compound and method for preparing the same | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-8471028-B2 | Optically active cyclic alcohol compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-1944291-B1 | Optically active cyclic alcohol compound and method for producing same | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-06-13 | — | — | EP | disclosed |
| EP-2371820-A1 | Optically active cyclic alcohol compound and method for preparing the same | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-7972836-B2 | Method of enzymatic optical resolution of racemic 4-hydroxy-1,2,3,4-tetrahydroquinoline | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME LLC | 2011-05-26 | — | — | US | disclosed |
| US-7868019-B2 | Dermatitis treating agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20100152451-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100130494-A1 | DERMATITIS TREATING AGENT (AS AMENDED) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20090269821-A1 | Method for Preparing Optically Active 4-Hydroxy-1,2,3,4-Tetrahydroquinoline Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1964925-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-1,2,3,4 -TETRAHYDROQUINOLINES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-03 | — | — | EP | disclosed |
| EP-1944291-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1941881-A1 | DERMATITIS REMEDIES | TANABE SEIYAKU CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130494-A1 | DERMATITIS TREATING AGENT (AS AMENDED) | AOX1, TLR7, MYD88 | RAB9A 4726/4885NPC1 3420/4885L3MBTL1 4529/4885 |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | RAB9A 693/4885NPC1 738/4885L3MBTL1 2821/4885 |
| US-20100152451-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | ADH1C, ADH1A, ADH5 | RAB9A 1609/4885NPC1 3168/4885L3MBTL1 3369/4885 |
| US-20130237708-A1 | Optically Active Cyclic Alcohol Compound And Method For Preparing The Same | ADH1C, ADH1A, ADH5 | RAB9A 1609/4885NPC1 3168/4885L3MBTL1 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.